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Review: Pharmacologic treatment
of warm autoimmune hemolytic
anemia
K.E. KING
The clinical course of warm autoimmune
hemolytic anemia (WAIHA) can be perplexing and
frustrating. Although many patients respond to
standard therapy in a predictable and timely fashion,
some patients are refractory to standard therapy and
may require several attempts of therapies that are less
well established. The focus of this review is to discuss
the various pharmacologic approaches and options for
the treatment ofWAIHA.
Corticosteroids
Corticosteroids are the initial therapy of choice for
WAIHA. A standard approach is to treat adults with
prednisone, 1 to 1.5 mg/kg per day (or 60 to 100
mg/day) for 1 to 3 weeks. Clinical response with
improvement in hematologic variables may be seen
within several days to 1 week. Approximately 80
percent of patients have a good initial response to this
therapy.1–3 Most patients who are going to respond will
respond within 2 weeks. If no response is noted within
3 weeks, steroid therapy has failed and alternative
therapeutic options should be considered.
For patients who improve with corticosteroid
therapy, the dosage of corticosteroids can be gradually
reduced only after stabilization of hematologic
variables. It is generally recommended to continue the
initial higher dose of steroids for 1 to 2 weeks after
achieving a response, weighing the benefits of
continued steroid therapy against the risks of this
therapy. After this period of stabilization, the steroid
dose should gradually be tapered. Sudden decreases in
dosage or rapidly progressive tapers can lead to
relapse. If relapse does occur, the dose should be
increased. Most clinicians consider a daily mainten-
ance dose of prednisone greater than 15 mg to achieve
a Hct of at least 30% a therapeutic failure, requiring
other interventions.
The adverse effects of corticosteroid therapy are well
established, and their severity should not be under-
estimated. Initial complications may include insomnia,
weight gain associated with increased appetite, and
emotional lability. Conditions such as diabetes and
hypertension may present or worsen, if preexisting.
Long-term corticosteroid therapy is complicated by the
development of a cushingoid habitus, osteoporosis,
and avascular necrosis. Ophthalmologic complications
include posterior subcapsular cataracts and glaucoma.
Patients are at increased risk of infection owing to
steroid-related immunosuppression. The complications
of steroid therapy can be quite severe; consequently,
steroids must be used judiciously and doses should be
tapered as quickly as possible.2,4
The explanation for clinical response to
corticosteroids is likely multifactorial. Steroids have
been shown to have an early effect on tissue
macrophages, which become less efficient at clearing
IgG- and C3-coated RBCs within the first 8 days of
therapy.5 Steroids may also affect antibody avidity.6
Only after several weeks of therapy is there a
significant decrease in antibody production.6
Permanent remission of WAIHA occurs in only
approximately 20 to 35 percent of adult patients.7,8
Consequently, additional therapy is generally planned
because clinical relapse is likely.
Splenectomy
Although the focus of this review is to provide an
overview of the pharmacologic options for the
treatment of autoimmune hemolytic anemia (AIHA), it
is difficult to discuss treatment options without
mentioning the role of splenectomy. Splenectomy has
traditionally been the second-line therapeutic
approach, after corticosteroid therapy; this may be in
transition as pharmacologic options are improving.
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Approximately 50 percent of patients withWAIHA
will have an excellent initial response to splenectomy,
although low doses of prednisone (< 15 mg/day) may
still be needed to maintain adequate hemoglobin
levels.9 Late relapses do occur, presumably as a result
of enhanced antibody synthesis and increased hepatic
sequestration.1,8
Although there is surgical morbidity and mortality
associated with splenectomy, the most significant risk
of adverse event related to splenectomy is over-
whelming postsplenectomy sepsis syndrome.
Infections with encapsulated bacteria represent a
medical emergency because there may be rapid
progression from an apparent flulike illness to
bacteremic shock, with hypotension and disseminated
intravascular coagulation. The risk of overwhelming
postsplenectomy sepsis syndrome has been quanti-
tated as 3.2 percent with a mortality rate of 1.4
percent.10 The risks of both infection and mortality can
be reduced by the use of pneumococcal and meningo-
coccal vaccines. Prophylactic antibiotic regimens are
controversial; however, many advocate the use of
penicillin (250 mg twice a day); amoxicillin or Bactrim
can be used as alternatives. Febrile illnesses in
splenectomized patients must be given prompt
attention and antibiotics administered expeditiously.
Because of this life-threatening risk associated with
splenectomy and because of the increasing pharma-
cologic options,many clinicians are no longer routinely
using splenectomy as a second approach after
corticosteroid therapy.
Immunosuppressive Agents
Several immunosuppressive agents have been
reported to be successful in the treatment of WAIHA,
but predominantly in case reports and small series. In
the past, these more intensive immunosuppressive
regimens were only considered when there is lack of
response to corticosteroids and splenectomy, when
there is relapse after corticosteroids and splenectomy,
when splenectomy is an unacceptable medical risk, or
when corticosteroid therapy cannot be tolerated.
Azathioprine
Azathioprine, an immunosuppressive antimetab-
olite, is an imidazolyl derivative of 6-mercaptopurine. It
is used for the prevention of renal allograft rejection, as
well as the treatment of autoimmune disorders, such as
rheumatoid arthritis (RA) and inflammatory bowel
disease.
Azathioprine has been used with reported success
in WAIHA. One study described 14 patients with idio-
pathicWAIHA who were treated with azathioprine;6 of
the patients (43%) achieved good response with
normal hemoglobin levels.11 In a report of 26 patients
with AIHA in the setting of systemic lupus
erythematosus (SLE), 2 patients received azathioprine
for relapse after successful initial response to
corticosteroids.12 Both patients achieved chronic
remission, and one of these patients was able to stop
steroid therapy after initiating azathioprine.
The generally recommended dose of azathioprine
for this indication is 1 to 2 mg/kg per day, or 75 to 200
mg/day in adults. If the patient is already taking
steroids and has a partial remission, the steroids should
be continued and tapered after a clinical response is
achieved. If after 3 to 4 weeks the patient has not
responded, the dosage may be increased (usually in
increments of 25 mg/day);however, the adverse effects
of azathioprine can be limiting.
The use of azathioprine is associated with gastro-
intestinal intolerance, including nausea, vomiting, and
diarrhea, and dose-related bone marrow suppression
with leukopenia and thrombocytopenia. Because
azathioprine is cytotoxic, its prolonged administration
is not advised because of the risk of development of a
neoplasm.
Cyclosporine
This lipophilic cyclic protein binds to cytoplasmic
proteins, called cyclophilins, and the resulting complex
inhibits calcineurin. Consequently, cyclosporine inhib-
its selected cytokine transcription,down-regulating the
transcription of some proinflammatory cytokines, and
it also inhibits T-lymphocyte activation. Cyclosporine is
used in the prophylaxis and treatment of solid-organ
transplant rejection and in the management of several
autoimmune disorders, including RA, ulcerative colitis,
and psoriasis.
Cyclosporine has been used with reported success
in the treatment of refractory WAIHA. Emilia and
associates13 described the successful use of
cyclosporine in the treatment of three patients with
AIHA and one patient with Evans’ syndrome. All
patients were refractory to multiple previous therapies
including steroids, splenectomy, and immunosup-
pressive agents. The patients were treated at an initial
total dose of 5 mg/kg per day given twice daily for 6
days with subsequent dose reduction to 3 mg/kg per
day, maintaining a serum cyclosporine level between
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200 and 400 ng/mL. Low-dose prednisone (5 mg/day)
was given to increase cyclosporine blood concentra-
tions. Dundar and colleagues14 reported similar
successful hematologic response in a patient with
Evans’ syndrome. The patient was refractory to
standard dose and high-dose corticosteroid therapy
and splenectomy, but responded to a cyclosporine
regimen with an initial dose of 10 mg/kg per day
gradually tapering to 4 mg/kg per day.
Others have successfully used cyclosporine in
combination with corticosteroid therapy. Hershko and
coworkers15 presented three patients, two with AIHA
and one with Evans’ syndrome, who relapsed despite
initial clinical response to steroids. All three patients
showed clinical improvement with cyclosporine
therapy (4 to 6 mg/kg per day) in addition to continued
corticosteroid therapy. A child with refractory Evans’
syndrome, who had failed corticosteroids and splen-
ectomy,was successfully treated with cyclosporine and
prednisone.16 Initially, the cyclosporine was given at 10
mg/kg per day and prednisone, at 2 mg/kg per day.
Each drug was gradually tapered, ultimately going to
alternate day cyclosporine and prednisone dosing.
One remarkable case is that of a 51-year-old woman
with SLE who had AIHA that was refractory to steroids,
splenectomy, cyclophosphamide, and azathioprine, but
who responded to cyclosporine therapy, allowing for
the corticosteroid tapering.17
Despite these reports of success, other authors
have reported failure in treating AIHA with
cyclosporine. Ferrara et al.18 reported a 27-year-old
man with AIHA in the setting of myelodysplastic
syndrome (MDS). In addition to being refractory to
cyclosporine, this patient did not respond to
corticosteroids or immunoglobulin. He was
successfully treated with a single high dose of
cyclophosphamide (4 g/m2).
The most common and significant adverse effect of
cyclosporine therapy is nephrotoxicity. Although
reversible acute azotemia can occur, irreversible
progressive renal disease may also occur. Because of
this significant risk of nephrotoxicity, patients taking
cyclosporine must be monitored closely. Other adverse
effects include hypertension, often related to renal
vasoconstriction, gastrointestinal intolerance, and
neurologic complications.
Mycophenolate Mofetil
After adsorption, mycophenolate mofetil is hydro-
lyzed to its active metabolite, mycophenolic acid,
which has potent cytostatic effects on lymphocytes. It
inhibits proliferation of T and B lymphocytes, and it
suppresses antibody production. This immunosup-
pressive agent is routinely used with cyclosporine and
corticosteroids for the prevention of renal, cardiac, and
hepatic allograft rejection. It may also be used to treat
psoriasis and proliferative lupus nephritis.
A few case reports suggest efficacy in the treatment
of WAIHA. Howard et al.19 reported treating four adult
patients with AIHA with mycophenolate mofetil. All
patients had failed previous therapy; two patients had
been treated with prednisone, splenectomy, azathio-
prine, and cyclosporine, and two patients were
previously treated with prednisone and cyclosporine.
Mycophenolate mofetil was dosed as follows: 500
mg/day increasing to 1 g/day after 2 weeks. All four
patients achieved a complete or good partial response
to therapy. Kotb and colleagues20 reported the use of
mycophenolate mofetil in the treatment of 13 patients
with autoimmune cytopenias, including 3 patients with
AIHA and 1 patient with Evans’ syndrome. The patients
with AIHA were refractory to steroids, immuno-
globulin, and cyclophosphamide. The same treatment
protocol was used for all patients; an initial dose of
mycophenolate mofetil 500 mg/day increasing to 1 to
3 g/day during the course of 1 to 2 weeks, depending
on the patient’s weight. Once therapeutic goals were
reached, other associated treatments were tapered and
stopped, followed by tapering of the mycophenolate
mofetil. Within 4 to 6 months, all 3 patients with AIHA
were independent of RBC transfusion. The patient
with Evans’ syndrome, who had been refractory to
high-dose steroids and immunoglobulin therapy,
responded within 6 weeks.
Mycophenolate mofetil has also been used to
successfully treat AIHA in the setting of several
underlying conditions. Zimmer-Molsberger and col-
leagues21 treated two patients who had received 2-
chlorodesoxyadenosine for underlying B-cell lympho-
cytic leukemia. Both patients had previously failed
corticosteroid treatment. One patient achieved trans-
fusion independence after mycophenolate mofetil
therapy. The other patient had a partial response but
was able to decrease his RBC requirement by more
than half. In the setting of MDS,Lin et al.22 reported the
successful use of mycophenolate mofetil. The patient
had failed corticosteroid therapy alone. Although
cyclosporine was tried, it was discontinued owing to
neurotoxicity. After starting mycophenolate therapy at
1 g/day with prednisolone (15 mg/day), prednisolone
was tapered and stopped within the following 3
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weeks. Four weeks after the initiation of mycopheno-
late mofetil, the patient was transfusion independent.
Alba and colleagues23 described the successful use of
mycophenolate in the treatment of two patients with
AIHA in the setting of SLE and antiphospholipid
syndrome. Both patients were given mycophenolate
mofetil (1 to 2 g/day) for the treatment of lupus
nephritis, but the authors noted an improvement in
hematologic variables temporally associated with the
mycophenolate mofetil therapy.
The adverse effects of mycophenolate mofetil tend
not to be as severe compared with other immunosup-
pressive drugs. Some patients may experience gastro-
intestinal intolerance, and myelosuppression may be
associated with this drug.
Cyclophosphamide
Cyclophosphamide is a cytotoxic, alkylating agent
that is rapidly absorbed and converted by the liver to
its active metabolite. It impairs DNA replication and
transcription, ultimately resulting in cell death. All
metabolites of the drug are excreted in the urine. The
degree of immunosuppression and cytotoxic effects
are related to the dose and duration of treatment.
Cyclophosphamide has been used in a variety of
dose regimens for the treatment of AIHA. One
suggested dosage is 1.5 to 2 mg/kg per day. If the
patient is already taking corticosteroids, the steroids
should be continued. If there is no hematologic
improvement after 4 weeks, the dose can be increased
in increments of 25 mg/day every 2 weeks.
Cyclophosphamide was successful in the treatment
of a 12-year-old girl with AIHA in the setting of giant
cell hepatitis.24 Although the etiology of giant cell
hepatitis has not been entirely elucidated, an immuno-
logic pathogenesis has been proposed. This patient
failed conventional dose and high-dose prednisone,
azathioprine, and IVIG. After the addition of cyclo-
phosphamide at a dose of 1.5 mg/kg per day to her
baseline prednisone and azathioprine, the patient
experienced resolution of both hematologic and
hepatic variables.
A report by Panceri et al.25 described a 5-month-old
boy who had life-threatening AIHA. This child was
refractory to steroids, high-dose immunoglobulin,
azathioprine, and splenectomy. The patient required
intensive transfusion support, receiving two to three
RBC transfusions per day. Because of the severity of the
clinical situation, the child was given high-dose
methylprednisolone (40 mg/kg per day) followed by
high-dose cyclophosphamide (10 mg/kg per day for 10
days). The child experienced striking, sudden
improvement, ultimately achieving complete recovery
without any major long-term complications.
Ferrara and colleagues18 described the successful
treatment of a 27-year-old man with refractory AIHA in
the setting of refractory anemia, a subtype of MDS. The
patient had failed the following treatments: high-dose
methylprednisolone, high-dose immunoglobulin, and
cyclosporine. The patient was treated with a single,
high dose of cyclophosphamide (4 g/m2) followed by
daily filgrastim in an effort to mobilize CD34+ cells. On
days 12 and 13, apheresis was performed to harvest
peripheral stem cells in anticipation of an autologous
peripheral stem cell transplant. The patient’s hema-
tologic counts recovered, and at 11 months’ follow-up,
his counts continued to be normal and he did not
require a stem cell transplant.
High-dose cyclophosphamide without stem cell
rescue was purposefully used by Moyo et al.26 They
report a series of nine patients with severe refractory
hemolytic anemia. All patients had failed a median of
three prior treatments (range,1 to 7). Patients received
cyclophosphamide 50 mg/kg per day for 4 days
followed on day 6 by daily granulocyte colony-
stimulating factor (5 µg/kg). This therapy successfully
reversed refractory disease, achieving complete
remission in six patients and partial remission in three
patients of the nine treated. These investigators have
subsequently reported successful use of this regimen
for the treatment of other refractory autoimmune
diseases, including SLE,27 myasthenia gravis,28 severe
aplastic anemia,29 and hepatitis-associated aplastic
anemia.30
The severity of the adverse effects related to
cyclophosphamide is dependent on the dose and
duration of therapy. The toxicities include bone
marrow suppression, increased susceptibility to
infection, infertility as a result of gonadal toxicity, risk
of malignancy, and bladder toxicities including cystitis
and risk of bladder cancer. When high-dose cyclo-
phosphamide is used, it is recommended to also give
mesna to prevent hemorrhagic cystitis. High-dose
regimens are also associated with nausea, alopecia, and
cardiac toxicity.
Danazol
Danazol is a semisynthetic, attenuated androgen
that was initially used for the treatment of endometri-
osis. Subsequently, it was found to be effective in the
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treatment of fibrocystic breast disease and hereditary
angioedema. Danazol has been helpful in a few cases
of WAIHA. Its mechanism of action is uncertain in this
clinical setting, although it has been suggested that it is
an immunomodulatory drug that may decrease IgG
production and reduce RBC-bound IgG and
complement.
In the largest report, Ahn31 described 28 patients
with AIHA who were treated with prednisone 20 to 60
mg/day and danazol 600 mg/day. Once the hemolysis
stopped, prednisone was tapered and ultimately
discontinued. Of the 13 patients with idiopathic AIHA,
77 percent of patients had an excellent or good
response. Fifteen of the patients had secondary AIHA
caused by an underlying condition, including 12
patients with SLE. Sixty percent of the patients with
secondary AIHA had an excellent or good response.
The author noted that the side effects of danazol
therapy were less than those of the steroids.
Pignon et al.32 reported on the use of danazol in 17
adults with AIHA. Ten patients were newly diagnosed,
and 7 patients were refractory to multiple therapies or
had relapsed after initial steroid therapy. Patients were
treated with prednisone (1 mg/kg per day) and danazol
(600 to 800 mg). Once hemolysis was controlled, the
prednisone was tapered or stopped. Long-lasting
responses were noted in 80 percent of the newly
diagnosed patients and in 60 percent of the previously
treated patients. Only minimal side effects occurred.
Chan and Sack33 reported a successful response to
danazol in one patient with SLE and severe AIHA. This
patient had been refractory to numerous therapies,
including corticosteroids, splenectomy, azathioprine,
chlorambucil, and IVIG.
In a series of 16 consecutive patients with SLE and
AIHA or Evans’ syndrome, danazol was given at an
initial dose of 200 mg/day and was increased stepwise
to a maximum dose of 1200 mg/day.34 All 16 patients
achieved a complete remission within 2 months after
starting danazol. Most patients tolerated the drug well;
however, some patients had undesirable side effects
including weight gain,dizziness,rash,hepatic adenoma,
cholestatic hepatitis, and pseudotumor cerebri.
Adverse effects include androgenic effects such as
acne,hair loss,hirsutism,and amenorrhea. More severe
effects also may be seen. Hepatic effects of danazol
include increased transaminases, cholestatic jaundice,
and hepatic adenoma. Changes in lipids may occur
with increased risk of atherosclerosis. There is also an




IVIG is manufactured from the pooled plasma of
healthy donors. After a fractionation process, the
product consists primarily of concentrated immuno-
globulin, largely IgG. It is well established as an effective
treatment for immune thrombocytopenic purpura
(ITP). Despite its efficacy in a seemingly related disease,
IVIG has not been shown to have comparable efficacy
in WAIHA. IVIG is recommended for the treatment of
AIHA only when patients are refractory or cannot
tolerate first-line therapy. In a recent review of the use
of IVIG in a large tertiary hospital, a total of 194 patients
were treated with IVIG in 2004;only 6 of these patients
(3%) were treated for AIHA.35
One study reported 37 patients in combination
with 36 patients from the literature; all 73 patients had
AIHA and were treated with IVIG.36 Overall, 29 of 73
patients (39.7%) responded to IVIG therapy. The
patients who responded were more likely to have
hepatomegaly (with and without splenomegaly) and
low initial hemoglobin. The authors suggest that IVIG
is not optimal as standard therapy for AIHA, but has a
role as adjunctive therapy especially for patients with
low initial hemoglobin or hepatomegaly, or for those
patients who cannot tolerate the toxicities of standard
therapy.
A subsequent case report described a man with
refractory and life-threatening AIHA in the setting of
primary antiphospholipid syndrome.37 He ultimately
responded to a 5-day course of IVIG at a dose of 400
mg/kg per day. At the completion of the initial course
of IVIG, hemolysis recurred and failed to respond to
subsequent steroids, azathioprine, and cyclosporine. A
second course of IVIG was successful in controlling his
hemolysis followed by weekly maintenance of 800
mg/kg IVIG.
The adverse effects of IVIG are predominantly
related to reactions occurring during infusion. Many of
these reactions,which are generally self-limited, can be
avoided by using a slower infusion rate. Consequently,
it is usually recommended to infuse the initial dose at a
slow rate, and, if well tolerated, the rate of infusion can
be increased for subsequent doses. Aside from
infusion-related adverse effects, the side effects of IVIG
therapy are usually well tolerated.
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Rituximab
Rituximab is a genetically engineered chimeric
murine/human monoclonal anti-CD20 antibody that
targets B-cell precursors and mature B cells; plasma
cells do not carry the CD20 antigen. Rituximab is
approved for the treatment of B-cell non-Hodgkin’s
lymphoma and B-cell chronic lymphocytic leukemia
(CLL). Surprisingly, success of rituximab has not been
limited to WAIHA secondary to B-cell neoplasms. The
typical dosing regimen of rituximab for the treatment
of WAIHA is 375 mg/m2, weekly for 2 to 4 weeks, with
some patients being treated for up to 12 weeks.38
Children with idiopathicWAIHA have responded to
rituximab therapy. Quartier and colleagues39 treated
five children with refractory idiopathic AIHA and one
child with AIHA after bone marrow transplantation. All
children were refractory to prednisone and other
therapies. The children ranged in age from 7 to 35
months. All patients achieved complete remission and
remained in remission with 15 to 22 months’ follow-up.
Of note, patients experienced prolonged absence of B
cells and hypogammaglobulinemia, such that five
patients received prophylactic IVIG replacement for 9
to 10 months after completing rituximab therapy.
Zecca et al.40 prospectively treated 15 children with
refractory AIHA. All patients had previously failed two
or more immunosuppressive therapies, and two of the
children had undergone splenectomy. Four of the
patients had underlying clinical conditions, including
SLE, RA, vitiligo, and prior bone marrow transplan-
tation. After completion of rituximab therapy, all
patients received IVIG for 6 months. With a median
follow-up of 13 months, 87 percent of patients (13 of
15) responded; 2 patients did not respond. Of the 13
patients who initially responded, 3 patients relapsed 7
to 10 months after therapy; all 3 patients responded to
a second course of rituximab therapy.
Numerous single case reports and small series of
adult patients report the successful use of rituximab in
the treatment of refractory AIHA. Ahrens and
colleagues41 report a 68-year-old man with refractory
disease who had failed previous therapies including
steroids, azathioprine, cyclophosphamide, and myco-
phenolate mofetil. The patient experienced minimal
side effects with chills associated with the first
infusion. The patient’s hemoglobin increased to 12.3
g/dL, and he became asymptomatic.
One of the larger series is reported by D’Arena and
coauthors.42 They report 11 adult patients with idio-
pathic WAIHA. Their retrospective analysis includes
refractory patients who had failed corticosteroids,
azathioprine, and high-dose immunoglobulins. At a
mean follow-up of 604 days, 8 patients (73%) had
achieved complete remission, and 3 patients (27%) had
a partial remission. All patients were transfusion
independent. The authors support the use of rituximab
for steroid-refractory disease.
Shanafelt and colleagues43 retrospectively reviewed
the experience of five patients with AIHA and four
patients with Evans’ syndrome. Complete response
occurred in two of the five patients (40%) with
refractory AIHA. One patient with Evans’ syndrome
had resolution of ITP, and one patient had a complete
response in AIHA; none of the patients with Evans’
syndrome had resolution of both.
In the setting of CLL, rituximab has been successful
in the treatment of AIHA. Narat et al.44 presented 11
patients with chronic WAIHA refractory to numerous
prior therapies. Of the 11 patients, 4 had underlying
CLL and 1 patient had Waldenström’s macroglobulin-
emia. Seven of the 11 patients (63.6%) responded to
rituximab therapy, with 3 patients in complete
remission and 4 patients in partial remission. The
authors noted that the median duration of response
was 11 months (range, 2.5 to 20 months).
D’Arena and coauthors45 reported 14 patients with
AIHA with underlying CLL. Three patients did not
complete the full course of four doses; 2 patients died
and 1 HCV-positive patient experienced a rise in amino
transferases. An increase in hemoglobin was seen in all
but 2 patients after rituximab therapy. Three patients
(22%) were considered to have a full response, and 7
patients (50%) had a partial response.
The adverse effects of rituximab include infusion-
related reactions, which may be quite severe. Patients
may experience fevers, chills, and rigors, and in more
severe cases, hypotension and even bronchospasm.
The drug is associated with prolonged B-cell depletion,
and, consequently, the risk of infection is long-lasting.
Alemtuzumab
Alemtuzumab, or Campath-1H, is a humanized rat
IgG1 monoclonal antibody directed against CD52,
which binds the cell membrane of lymphocytes,both B
cells and T cells. This drug can induce a prolonged
lymphopenia leading to extensive and long-lasting
immunosuppression. The drug is used in the treatment
of CLL, and it has been incorporated into stem cell
transplant regimens.
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There are far fewer reports on the use of
alemtuzumab for the treatment of AIHA, most likely
reflecting a relative lack of experience with this drug.
Willis and colleagues46 report 21 patients with
refractory autoimmune cytopenias, including 2 patients
with WAIHA and 3 patients with Evans’ syndrome.
Campath-1H was given as a 10-mg daily dose for 10
days. The patients with WAIHA both responded to
therapy, one with a complete response and the other
with a partial response. Two of the patients with Evans’
syndrome responded, but both subsequently relapsed.
In a particularly dramatic case, a 58-year-old man
with refractory AIHA failed numerous therapies,
including steroids, azathioprine, splenectomy, and even
rituximab.47 This patient successfully responded after a
regimen of alemtuzumab of 3 mg on day 1, 10 mg on
day 3, and 30 mg on day 5, followed by 30 mg three
times per week for 8 weeks. After this regimen, the
patient’s transfusion requirements decreased dramati-
cally, and the alemtuzumab was gradually tapered. The
patient experienced infusion-related chills and
reactivation of CMV, requiring ganciclovir treatment.
Several small reports discuss the successful
treatment of refractory AIHA in the setting of CLL.
Karlsson and colleagues48 reported five patients with B-
cell CLL complicated by AIHA. The patients were
transfusion dependent and refractory to previous
therapy for AIHA including steroids and, in select
patients, immunoglobulins, cyclosporine, cyclophos-
phamide, and rituximab in two patients. Patients were
treated with an initial dose of 3 mg or 10 mg of
alemtuzumab administered either subcutaneously or as
an intravenous infusion. The doses were gradually
increased to 30 mg, given three times per week for 12
weeks. All five patients responded with an increase in
hemoglobin of more than 2 g/dL, no longer requiring
transfusion support. At the end of treatment, the mean
hemoglobin was 11.9 g/dL,and after 12 months’ follow-
up, the mean hemoglobin was 12.5 mg/dL.
The side effects related to alemtuzumab are
predominantly infusion related, including fevers and
chills. The most significant adverse effect of the
treatment is prolonged lymphopenia and immuno-
suppression.
Eculizumab
This humanized monoclonal antibody is directed
against the terminal complement protein C5. The
antibody prevents cleavage of C5 into its proinflam-
matory components, inhibiting terminal complement
activation. The drug has recently been approved for
use in patients with paroxysmal nocturnal hemo-
globinuria (PNH). In the initial study, 11 patients with
PNH were treated with eculizumab using a regimen of
600 mg/week for 4 weeks, followed by 900 mg/week
every other week through week 12. This study found
eculizumab to be effective in reducing intravascular
hemolysis, hemoglobinuria, and the need for trans-
fusion in patients with PNH.49 In an extension of the
initial trial, the authors evaluated the long-term safety
and response of eculizumab in the same 11 patients;
the drug was found to have continued long-term
efficacy and safety.50 In a subsequent double-blind,
multicenter trial, 87 patients were randomized to
receive either placebo or eculizumab. This definitive
trial confirmed the prior findings, with eculizumab
reducing intravascular hemolysis and transfusion
requirements with improvement in quality of life for
patients with PNH.51
Although there are no reports to date in which
eculizumab has been used in the treatment of AIHA,
one must ask whether this drug would be useful
particularly in refractory, life-threatening cases in
which intravascular hemolysis is a key feature. In most
cases of WAIHA, the hemolytic process is predomi-
nantly extravascular. But we have all been haunted by
the unusual, troublesome patient who has a significant
component of intravascular hemolysis. Perhaps it is in
this setting of uncontrollable, refractory, and life-
threatening intravascular hemolysis that eculizumab,or
another complement inhibitory drug,may play a role in
stabilizing the intravascular hemolysis, allowing the
time for other therapeutics to be effective.
Conclusion
In an attempt to focus on the pharmacologic
treatments ofWAIHA, this review deliberately omits the
role of transfusion therapy. Appropriate transfusion
management is critical in the treatment of patients
with life-threatening anemia, particularly those with a
brisk hemolytic rate or reticulocytopenia. Transfusions
may be needed for initial stabilization and should be
anticipated during the patient’s clinical course, such
that appropriate serologic evaluations can be
completed and optimal RBCs can be selected.
The therapeutic options for treating WAIHA are
increasing with new immunosuppressive agents,
monoclonal antibody preparations, and potentially
complement inhibitory drugs. Despite these
increasing therapeutic options, recommended initial
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treatment remains corticosteroid therapy followed by a
second-line approach of splenectomy. Because of the
invasive nature of splenectomy and the lifelong risk of
overwhelming postsplenectomy sepsis syndrome, in
practice many clinicians are currently opting for
pharmacologic agents, especially rituximab, as a
second-line approach instead of splenectomy. One
must be well aware that there are few definitive trials
to support the use of these pharmacologic therapies as
a second-line approach. The majority of the supportive
evidence is based on case reports and small series of
patients.
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